Criteria Bio Ventures
VC Fund
Barcelona, Spain
Criteria Bio Ventures is a VC fund in Barcelona focused on Biotechnology and Health Care. Criteria Bio Ventures Life Sciences venture fund backing private biotech companies in Europe and North America with a special focus on Spain and Portugal.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 43%
Last updated:
For AI agents: llms.txt
Industries Criteria Bio Ventures invests in
Stages Criteria Bio Ventures invests in
Countries Criteria Bio Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Pre-Seed
- $3.5M–$3.5M
- Series A
- $29M–$83M
Investment Focus
Industry
- Biotechnology 6 (86%)
- Health Care 2 (29%)
- Life Science 2 (29%)
- CRM 1 (14%)
- Medical 1 (14%)
Stage
- Series A 2 (29%)
- Seed 1 (14%)
- Pre-Seed 1 (14%)
- Series B 1 (14%)
- Venture - Series Unknown 1 (14%)
Country
- Spain 2 (29%)
- United Kingdom 2 (29%)
- France 1 (14%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Pablo Cironi
Managing Director
|
Managing Director | Total investments: 5 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Cytospire Therapeutics is bringing forward a portfolio of next generation immune cell engagers. | $82.6M / Series A / May 05, 2026 | ||
| Adaptam Therapeutics is at the forefront of next-generation cancer immunotherapies | $3.5M / Pre-Seed / Oct 27, 2025 | ||
| NRG Therapeutics is a drug discovery company focussed on therapeutic approaches that will restore mitochondrial function and slow or halt the progression of neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease and motor neurone disease. Founded in 2018 by a team of experienced biotech and pharmaceutical industryprofessionals, with a background in neuroscience drug discovery, NRG Therapeutics will initially focus on the discovery and development of brain penetrant mitochondrial permeability transition pore inhibitors for the treatment of Parkinson’s disease. | $67.8M / Series B / Sep 08, 2025 | ||
| Tolerance Bio is a biopharmaceutical company focused on manipulating immune tolerance via the thymus to address various immune-mediated diseases thymus. | $20.2M / Seed / Oct 15, 2024 | ||
| Medlumics is a medical device start-up born in 2009 from a compromise with improving human living standards by means of technology. | Venture - Series Unknown / Jul 29, 2024 | ||
| AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance. | $29.2M / Series A / Sep 18, 2023 | ||
| See all 7 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Criteria Bio Ventures invest in?
Criteria Bio Ventures invests primarily in Biotechnology, Health Care and Life Science startups, most often at Series A and Seed stage. Most of the 7 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Criteria Bio Ventures invest in?
Criteria Bio Ventures typically joins rounds of $3.5M–$3.5M at Pre-Seed and $29M–$83M at Series A. These are whole funding-round sizes, not Criteria Bio Ventures's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Criteria Bio Ventures took part in.
How do I contact Criteria Bio Ventures?
Public channels for Criteria Bio Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Criteria Bio Ventures?
The team at Criteria Bio Ventures includes Pablo Cironi (Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Nov 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
